-
The relationship between cumulative risk and health‐related quality of life in youth with sickle cell disease: Moderating effects of secondary control engagement coping Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-16 Elise M. Belkin, Natalie Koskela‐Staples, Elise Turner, L. Vandy Black, David A. Fedele
BackgroundYouth with sickle cell disease (SCD) often experience low health‐related quality of life (HRQOL). Engagement in resilience‐promoting processes, such as secondary control engagement (SCE) coping, or adapting to stressors, may be linked to contextual risk factors (e.g., poverty status). This study aims to illuminate relationships between a cumulative risk index (CRI), SCE coping, and HRQOL
-
Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-15 Juwon Yim, Afrin Jahan, Nikolay Braykov, Nina D. Murphy, Gary M. Woods
BackgroundEnoxaparin is an anticoagulant used for pharmacologic thromboprophylaxis in pediatrics. Enoxaparin pharmacokinetics can be altered in the setting of obesity. Optimal enoxaparin dosing for thromboprophylaxis in children with obesity remains unclear.ProcedureA retrospective review was conducted of pediatric patients who weighed ≥60 kg with BMI ≥ 95th percentile, received enoxaparin for thromboprophylaxis
-
Sequelae and post‐thrombotic syndrome after venous thromboembolism in acute lymphoblastic leukemia survivors treated on the NOPHO ALL2008 protocol Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-14 Merete Dam, Line Stensig Lynggaard, Ólafur G. Jónsson, Sonata Saulyte Trakymiene, Katrin Palk, Kirsten Jarvis, Liv Andrés‐Jensen, Ruta Tuckuviene, Birgitte Klug Albertsen
The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post‐thrombotic syndrome (PTS), a group of signs and symptoms developed as a complication to deep venous thrombosis (DVT), imposing risk of permanent disability and reduced quality of life (QoL). PTS prevalence ranges from
-
Comment on: Sarcopenia in long‐term survivors of cancer in childhood and adolescence: A cross‐sectional study of calf muscle mass by peripheral quantitative computed tomography with an examination of the muscle‐bone unit Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-13 Ahmad J. Abdulsalam, Murat Kara, Levent Özçakar
-
Description of a national, multi-center registry of patients with sickle cell disease and SARS-CoV-2 infection: Data from the Pediatric COVID-19 United States Registry Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-12 Aleksandra S. Dain, Caroline Diorio, Brian T. Fisher, Jane S. Hankins, Char M. Witmer, Mickael Boustany, Madeline Burton, Jose Ferrolino, Salma Sadaf, Hailey S. Ross, Gabriela Maron
Children with sickle cell disease (SCD) are at risk of complications from viral infections, including SARS-CoV-2. We present the clinical characteristics and outcomes of pediatric patients with SCD from the Pediatric COVID-19 United States Registry who developed acute COVID-19 due to SARS-CoV-2 infection (n = 259) or multisystem inflammatory syndrome in children (MIS-C; n = 4). Nearly half of hospitalized
-
Targeting BCL11A through gene therapy in sickle cell disease: Will one size fit all or most? Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-12 Abdulrahman Alsultan
-
Social impairment in survivors of pediatric brain tumors via reduced social attention and emotion‐specific facial expression recognition Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-12 Peter M. Fantozzi, Ashley Anil, Sean McHugh, Alannah R. Srsich, Manali Zope, Julia Parish‐Morris, Robert T. Schultz, John Herrington, Matthew C. Hocking
Background/objectivesSurvivors of pediatric brain tumors (SPBT) experience significant social challenges, including fewer friends and greater isolation than peers. Difficulties in face processing and visual social attention have been implicated in these outcomes. This study evaluated facial expression recognition (FER), social attention, and their associations with social impairments in SPBT.MethodsSPBT
-
Feasibility study of micronutrient status and body mass index of newly diagnosed pediatric oncology patients: Research commentary Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Paul C. Rogers, Jeffrey Cheng, Alecia Lim, James E. Potts
We conducted a feasibility study to evaluate micronutrients and body mass index (BMI). Fat soluble vitamins A, D, E and trace elements copper (Cu), selenium (Se), and zinc (Zn) levels were evaluated. Weight, height, BMI, and Z‐scores were recorded. Side effects or specific adverse events were documented. No patient had a Z‐score for height, weight, or BMI of less than 2 SD or greater than 2 SD. Ninety
-
Heterozygous TCF3‐related disease presenting as X‐linked agammaglobulinemia mimicry in a male toddler with B‐cell aplasia, agammaglobulinemia, and severe neutropenia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Laura M. Bou‐Maroun, Kelly J. Walkovich, Lauren Frazier, Mark Hannibal, Thomas F. Michniacki
-
Primary myeloid sarcoma in an infant with an NRAS mutation Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Aarti Kamat, Valerie Opipari, Clayton Habiger, Rama Jasty, Rajen Mody, Laura Sedig
-
Pediatric splenic infarction: Assessment of associated clinical conditions and outcome Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Evgeny Grishin, Michalle Soudack, Sarina Levy‐Mendelovich, Yael Bezalel, Aharon Lubetsky, Omri Cohen, Tami Brutman‐Barazani, Orly Efros, Gili Kenet, Assaf A. Barg
Pediatric splenic infarction (SI) is rare yet clinically significant. Publications regarding this complication are mostly limited to case reports. This is a retrospective study examining SI etiology, clinical presentation, management, and outcomes among children. Twenty‐two patients (median age: 7.9 years) were included, mostly with pre‐existing hematological diseases. Splenomegaly (72%), thrombocytopenia
-
Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Fathia Oladipupo, Joseph Stanek, Joseph Walden, Jennifer Young, Melissa J. Rose, Kathleen Nicol, Anthony Villella, Susan Creary
Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was
-
Adequate menstrual suppression in adolescents with inherited bleeding disorders often requires multiple treatment changes: Retrospective cohort study of a multidisciplinary clinic Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Megan C. Brown, Kelly Tickle, Kalinda Woods, Robert F. Sidonio
Heavy menstrual bleeding (HMB) is often the presenting symptom for females with inherited bleeding disorders (IBD). Multidisciplinary clinics leverage the expertise of hematologists and women's health specialists. This study characterizes the complexity of HMB management for adolescents with IBDs from a large multidisciplinary clinic. Adolescents often required multiple different menstrual suppression
-
Single centre experience of the use of emicizumab in previously untreated and minimally treated patients under 18 months of age Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-11 Eman Hassan, Jayashree Motwani
Emicizumab has revolutionised haemophilia A treatment landscape and significantly reduced treatment burden, particularly in the paediatric population. We conducted a retrospective study, focused on infants aged ≤18 months with severe haemophilia A. The study included 16 patients, with a median age of 8.2 months and median treatment duration of 61.6 weeks. Before commencing emicizumab, six patients
-
Real‐world experience of direct oral anticoagulant use in a single pediatric center Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-07 Gianna G. Valenti, Cynthia Sabo, Michelle Hyde, Madhvi Rajpurkar
BackgroundPediatric venous thromboembolism has increased by 130%–200%, specifically in hospitalized children, and direct oral anticoagulants (DOACs) offer several therapeutic advantages.MethodsThis study aims to evaluate the real‐world epidemiological and outcome data from a retrospective review of pediatric patients treated with DOACs from January 1, 2013 to December 31, 2022. In this single‐center
-
How we use angiopoietin‐2 in the diagnosis and management of vascular anomalies Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-05 Elissa R. Engel, Timothy D. Le Cras, Kiersten W. Ricci
The diagnosis of vascular anomalies remains challenging due to significant clinical heterogeneity and uncertain etiology. Evaluation using biopsy and/or genetic testing for somatic variants is invasive, expensive, and prone to sampling error. There is great need for noninvasive and easily measured blood laboratory biomarkers that can aid not only in diagnosis, but also management of treatments for
-
-
Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA‐JMML‐001 trial Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-04 Franco Locatelli, Karin Belander Strålin, Irene Schmid, Julián Sevilla, Owen P. Smith, Marry M. van den Heuvel‐Eibrink, Marco Zecca, Christian M. Zwaan, Allison Gaudy, Meera Patturajan, Jennifer Poon, Mathew Simcock, Charlotte M. Niemeyer
Here we report efficacy, pharmacokinetics, and safety data obtained in treatment‐naive, pediatric patients with newly diagnosed advanced MDS receiving azacitidine in the AZA‐JMML‐001 study. The primary endpoint was response rate (proportion of patients with complete response [CR], partial response [PR], or marrow CR, sustained for ≥4 weeks). Of the 10 patients enrolled, one had an unconfirmed marrow
-
Use of modern three‐dimensional imaging models to guide surgical planning for local control of pediatric extracranial solid tumors Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-02 Nikhil R. Shah, William J. Weadock, Keyonna M. Williams, Rebecca Moreci, Tammy Stoll, Aparna Joshi, Robin Petroze, Erika A. Newman
IntroductionIn complex pediatric surgical oncology, surgical planning is contingent upon data gathered from preoperative imaging. Three‐dimensional (3D) modeling and printing has been shown to be beneficial for adult presurgical planning, though pediatric literature is less robust. The study reviews our institutional experience with the use of 3D image segmentation and printed models in approaching
-
Hypofractionated re‐irradiation for diffuse intrinsic pontine glioma Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-03-02 Nikhil P. Mankuzhy, Kathryn R. Tringale, Ira J. Dunkel, Sameer Farouk Sait, Mark M. Souweidane, Yasmin Khakoo, Matthias A. Karajannis, Suzanne Wolden
BackgroundRe‐irradiation (reRT) increases survival in locally recurrent diffuse intrinsic pontine glioma (DIPG). There is no standard dose and fractionation for reRT, but conventional fractionation (CF) is typically used. We report our institutional experience of reRT for DIPG, which includes hypofractionation (HF).MethodsWe reviewed pediatric patients treated with brainstem reRT for DIPG at our institution
-
Phantosmia during proton radiation and differences in frequency of phantosmia rates based on proton craniospinal irradiation technique for pediatric brain tumor patients Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-29 Myrsini Ioakeim‐Ioannidou, Juliane Daartz, Parsa Erfani, Tobias Urell, Arthur Lalonde, Julia Berv, Shannon Leahy, Barbara Fullerton, Rachel Bolton, Torunn Yock, Nancy Tarbell, Beow Yeap, Shannon M MacDonald
BackgroundUnusual olfactory perception, often referred to as “phantosmia” or “cacosmia” has been reported during brain radiotherapy (RT), but is infrequent and does not typically interfere with the ability to deliver treatment. We seek to determine the rate of phantosmia for patients treated with proton craniospinal irradiation (CSI) and identify any potential clinical or treatment‐related associations
-
Adenoid cystic carcinoma of the parotid and submandibular glands in children and young adults: A population‐based study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-29 Alisa L. Phillips, Cai Li, Jia Liang, Anthony Sheyn, Jeffrey C. Rastatter, Daniel C. Chelius, Daniel Orbach, Celine Richard
ObjectivesThis study aims to analyze the behavior and treatment of adenoid cystic carcinoma (AdCC) in the pediatric and young adult population and to identify factors affecting overall survival (OS).Materials and methodsThe study analyzed salivary gland malignancies in patients aged 0–21 with AdCC histology using the National Cancer Database from 2004 to 2018.ResultsA total of 72 patients (59.7% parotid
-
The ASPHO 2024 Distinguished Career Award goes to Dr. David A. Williams Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-29 Akiko Shimamura
-
Primary testicular T lymphoblastic lymphoma in a child: Case report from a regional cancer center Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-29 Sathya Murugasamy, Arun Kumar, Hemavathi Narayan, Lingegowda Appaji, Nuthan Kumar, Prakruthi S. Kaushik, Mohana Reddy, Nikila Ravichandran, Thirumala Rupakumar, Meena Haldorai, Avinash Thumallapalli, Bangegadde S. Aruna Kumari
-
Authors’ reply: Intravenous iron for pediatric critically ill children Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-27 Laura Butragueño‐Laiseca, Sara de la Mata Navazo, Amelia Caridad Sánchez Galindo, María José Santiago Lozano
-
you leave a hole Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-27 Erica C. Kaye
CONFLICT OF INTEREST STATEMENT The author declares no conflicts of interest.
-
Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-27 Jenny Ruiz, Rebecca K. Kelly, Richard Aplenc, Theodore W. Laetsch, Alix E. Seif
Normal absolute neutrophil count (ANC) variations, as seen with Duffy‐null associated neutrophil count (DANC), are not accounted for in trial eligibility, which may contribute to racial enrollment disparities. We describe ANC eligibility for pediatric oncology phase I/II clinical trials according to primary sponsorship from 2010 to 2023 using ClinicalTrials.gov. Out of 438 trials, 20% were industry‐sponsored
-
Hematopoietic stem cell transplantation in two sisters with bone marrow failure associated with POLE gene variants Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-26 Kentaro Fujimori, Norihito Ikenobe, Yoshihiro Gocho, Toru Uchiyama, Takao Deguchi, Hirotoshi Sakaguchi, Daisuke Tomizawa, Ichiro Takeuchi, Hirotaka Shimizu, Katsuhiro Arai, Akira Ishiguro, Kimikazu Matsumoto, Akihiro Iguchi
-
-
Oh rats! Intracellular rod‐like inclusions in an adolescent with Shwachman–Diamond syndrome Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-23 Jonathan Mayhew, Harrison Luttrell, Kathryn Barros, Lindsay Blazin, Cydney Nichols, Nidhi Avashia‐Khemka, John‐Paul Lavik, Ryan F. Relich, Deryll Skinner, Jiehao Zhou, Amanda Saraf, Alka Khaitan
-
Pancreatic iron in pediatric transfusion‐dependent beta‐thalassemia patients: A longitudinal MRI study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-22 Antonella Meloni, Laura Pistoia, Maria Caterina Putti, Filomena Longo, Elisabetta Corigliano, Paolo Ricchi, Vincenza Rossi, Tommaso Casini, Riccardo Righi, Stefania Renne, Giuseppe Peritore, Luigi Barbuto, Vincenzo Positano, Filippo Cademartiri
BackgroundIn pediatric transfusion‐dependent thalassemia (TDT) patients, we evaluated the prevalence, pattern, and clinical associations of pancreatic siderosis and the changes in pancreatic iron levels and their association with baseline and changes in total body iron balance.ProcedureWe considered 86 pediatric TDT patients consecutively enrolled in the Extension‐Myocardial Iron Overload in Thalassemia
-
Delayed serum sickness reaction after initial hypersensitivity reaction to calaspargase during treatment for B‐cell acute lymphoblastic leukemia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-21 Kelsey Gay, Gayle Smink, Kevin Mulieri, Smita Dandekar
-
The evidence is mounting: Insurance coverage disruptions lead to worse outcomes among children diagnosed with cancer Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-21 Philip J. Lupo, Christina L. Magyar
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Assessing coagulopathy and endothelial dysfunction in pediatric venous malformation: A thromboelastometry and syndecan‐1 study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-19 Francisco Nava y Hurtado, Elena Monzon Manzano, Vanesa Viana‐Huete, Paloma Triana Junco, Maria Teresa Alvarez‐Roman, Elena G. Arias‐Salgado, Nora Butta, Juan Carlos Lopez Gutierrez
ObjectiveThe occurrence of unpredictable pain crises are the principal determinant of the quality of life for patients with venous malformations (VM). A definite coagulation phenomenon, characterized by an increase in D‐dimer levels and the presence of phleboliths within the malformation, has been previously reported. By applying Virchow's triad and evaluating intralesional samples, our objective is
-
Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE-related immune thrombocytopenia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-13 Dafna Brik-Simon, Orly Efros, Yoel Levinsky, Gil Amarilyo, Irit Tirosh, Sarina Levy-Mendelovich, Orna Steinberg-Shemer, Shai Izraeli, Joanne Yacobovich, Oded Gilad
Pediatric immune thrombocytopenia (ITP) may precede systemic autoimmune disorders. In adolescent patients with ITP, routine screening for systemic lupus erythematosus (SLE) may be performed by testing for antinuclear antibody (ANA) titer. Hydroxychloroquine (HCQ) is a safe and effective immunomodulatory drug in patients with SLE but rarely used in ITP. We analyzed the platelet count response and safety
-
Electrocardiographic abnormalities in patients with sickle cell disease: A systematic review and meta-analysis Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-13 Erfan Taherifard, Hamed Movahed, Ehsan Taherifard, Alireza Sadeghi, Niloofar Dehdari Ebrahimi, Alireza Ahmadkhani, Fatemeh Kheshti, Hossein Movahed
Previous studies have documented that electrocardiography (ECG) can reveal a range of abnormalities, offering valuable insights into the cardiac evaluation of patients with sickle cell disease (SCD). The objective of this study is to assess the patterns of ECG abnormalities observed in these patients with SCD, and to determine their prevalence.
-
Pain screening in youth with sickle cell disease: A quality improvement study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-13 Dennis C. Vroom, Samuel N. Rodgers-Melnick, Tracie Brown, Amma Owusu-Ansah, Jeffery A. Dusek
Youth with sickle cell disease (SCD) face several challenges as they age, including increased pain frequency, duration, and interference. The purpose of this study was to (i) determine the feasibility of routine pain screening; (ii) identify and describe various clinical pain presentations; and (iii) understand preferences/resources related to engaging in integrative health and medicine (IHM) modalities
-
Shifting perspectives and transformative change: Parent perspectives of an active music engagement intervention for themselves and their child with cancer Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-09 Kristin Stegenga, Amanda K. Henley, Elizabeth Harman, Sheri L. Robb
Children with cancer (ages 3–8 years) and their parents experience significant, interrelated distress associated with cancer treatment. Active music engagement (AME) uses music-based play and shared music-making to mitigate this distress. To advance our understanding about how AME works and its essential features, we interviewed parents who received the AME intervention as part of a multi-site mechanistic
-
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-06 Nancy S. Green, Deepa Manwani, Banu Aygun, Abena Appiah-Kubi, Kim Smith-Whitley, Yina Castillo, Lucy Soriano, Haomiao Jia, Arlene M. Smaldone
Despite disease-modifying effects of hydroxyurea on sickle cell disease (SCD), poor adherence among affected youth commonly impedes treatment impact. Following our prior feasibility trial, the “Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT)” multi-site randomized controlled efficacy trial aimed to increase hydroxyurea adherence for youth with SCD ages 10–18 years. Impaired
-
Successful use of tacrolimus for treatment-refractory neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: A case series Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-06 Sara Delap, Nilay Shah, Olivia Kuns, Bianca Franklin, Micah A. Skeens
Opsoclonus-myoclonus-ataxia syndrome (OMAS) is an autoimmune central nervous system disorder, primarily manifesting as a paraneoplastic sequalae to neuroblastoma, and characterized by motor disorders and behavioral disturbances. OMAS is typified by aberrant B-cell and T-cell activation. Current treatment involves immunosuppression using corticosteroids, intravenous immunoglobulin, and rituximab. However
-
Temporal trends of splenectomy in pediatric hospitalizations with hereditary spherocytosis from 2000 to 2019: A national survey Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-05 Leonardo Guizzetti
Total and partial splenectomy are used in pediatric patients with hereditary spherocytosis to resolve anemia and hemolytic complications.
-
The AYA gap for rhabdomyosarcoma Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-04 Simone Hettmer, Lars H. Lindner
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-04 Kira Feldman, Kathryn Aaronson, Tina Gu, Kelsey Ige, Erica Southworth, Lauren Sanchez, Elliot Stieglitz
Pegaspargase is a therapeutic enzyme that is utilized in treatment regimens targeting pediatric acute lymphoblastic leukemia. However, many patients experience hypersensitivity reactions, requiring discontinuation of the therapy. Historically, this necessitated switching to an alternative form of the drug, most commonly asparaginase Erwinia chrysanthemi; however, in recent years this was difficult
-
Social determinants of health predict health outcomes following pediatric allogeneic hematopoietic stem cell transplant Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-01 Kimberly L. Klages, Laura E. Schwartz, Endia J. Santee Crabtree, Cole Brokamp, Erika Rasnick, Christopher E. Dandoy, Stella M. Davies, Ahna L. H. Pai
Pediatric hematopoietic stem cell transplantation (HCT) is an intensive medical procedure that places substantial financial and logistical burdens on families and is associated with significant health risks, such as graft-versus-host disease (GVHD), and infections. The influence of the social determinants of health (SDoH) on outcomes following pediatric HCT is understudied. This study aimed to examine
-
Financial assistance and other financial coping strategies after a pediatric cancer diagnosis Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-02-01 Jackie J. Lin, Erica M. Evans, Kathleen Praxedes, Anurag K. Agrawal, Lena E. Winestone
Families experience financial burden and household material hardship (HMH) after a pediatric cancer diagnosis. This study investigates types of financial assistance and other financial coping strategies (FCS) adopted by families during the first year after diagnosis.
-
Neonatal hemophagocytic lymphohistiocytosis: A meta-analysis of 205 cases Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-31 Lincoln A. Kranz, Wyatt S. Hahn, Whitney S. Thompson, Roland Hentz, Nathan L. Kobrinsky, Paul Galardy, Jacob R. Greenmyer
Neonatal hemophagocytic lymphohistiocytosis (nHLH), defined as HLH that presents in the first month of life, is clinically devastating. There have been few large descriptive studies of nHLH.
-
Local treatment in initially unresected non-rhabdomyosarcoma soft-tissue sarcomas of children and adolescents: A retrospective single-center experience Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-31 Andrea Ferrari, Sabina Vennarini, Marco Fiore, Luca Bergamaschi, Stefano Chiaravalli, Carlo Morosi, Chiara Colombo, Emilia Pecori, Nadia Puma, Roberto Luksch, Monica Terenziani, Filippo Spreafico, Cristina Meazza, Marta Podda, Veronica Biassoni, Elisabetta Schiavello, Maura Massimino, Michela Casanova
Pediatric non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS) are a heterogeneous group of aggressive tumors. Patients with locally advanced/initially unresected disease represent a subset of patients with unsatisfactory outcome: limited data are available on the best treatment approach, in particular regarding local therapy.
-
Outcomes for pediatric acute lymphoblastic leukemia patients with intestinal perforation Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-30 Gustavo de Oliveira Canedo, Aodhnait S. Fahy, Eveline Lapidus Krol, Oussama Abla, Priscilla P. L. Chiu
Intestinal perforation during acute lymphoblastic leukemia (ALL) treatment in children is rare, but represents a severe complication with possible long-term consequences. In this study, we aim to provide an overview of the epidemiology and clinical characteristics of these patients; analyze surgical pathology findings for possible causes; and determine its impact on patients’ therapy, nutritional status
-
Clinical practice guideline-inconsistent management of fever and neutropenia in pediatric oncology: A Children's Oncology Group study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-30 L. Lee Dupuis, Brian T. Fisher, A. J. Sugalski, Allison Caren Grimes, Michelle Nuño, S. Ramakrishnan, M. P. Beauchemin, Paula D. Robinson, Nancy Santesso, Alexandra Walsh, A. R. Wrightson, Lolie Yu, Susan K. Parsons, Lillian Sung
The primary objective was to measure the proportion of episodes where care delivery was inconsistent with selected recommendations of a clinical practice guideline (CPG) on fever and neutropenia (FN) management. The influence of site size on CPG-inconsistent care delivery, and association between patient outcomes and CPG-inconsistent care were described.
-
Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single-center retrospective study Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-30 Sean Schoeman, Rochelle Bagatell, Anne Marie Cahill, John Maris, Peter Mattei, Yael Mosse, Jennifer Pogoriler, Abhay Srinivasan, Michael Acord
To determine whether percutaneous core needle biopsy (PCNB) is adequate for the diagnosis and full molecular characterization of newly diagnosed neuroblastoma.
-
Translation, transcultural adaptation, and validation of PedsQL 3.0 Sickle Cell Disease Module into Brazilian Portuguese Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-29 Maristela G. Olival, Thiago S. Vilela, Jane S. Hankins, Cristiane B. Bendo, Clarisse L. Lobo, Maria Christina P. Maioli, Flávia M. Bandeira, Guilherme L. Werneck, Andréa R. Soares
Despite the high prevalence of sickle cell disease (SCD) in Brazil, no studies have described the validation of an SCD-specific health-related quality-of-life (HRQoL) instrument in children. We validated PedsQL 3.0 Sickle Cell Disease Module (PedsQL-SCD) for Brazilian Portuguese, and cross-validated it with PedsQL 4.0 Generic Core Scale (PedsQL-GCS) in children with SCD.
-
Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-28 Douglas J. Harrison, Amira Qumseya, Wei Xue, Michael Arnold, Timothy B. Lautz, Susan M. Hiniker, Stefanie M. Thomas, Rajkumar Venkatramani, Aaron R. Weiss, Leo Mascarenhas
The impact of established prognostic factors on survival outcomes for childhood rhabdomyosarcoma (RMS) have not been well described in the adolescent and young adult (AYA) RMS patient population.
-
Pediatric oncology provider perspectives and patient/family perceptions of chemotherapy-induced nausea and vomiting management: Experiences at an academic medical center Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-27 Hadley Bloomhardt, Melissa Rubin, Yanling Xue, Zhezhen Jin, Laura Masino, Drew Seidel, Nobuko Hijiya, Melissa Beauchemin
Chemotherapy-induced nausea and vomiting (CINV) is common in children undergoing cancer treatment, and significantly impacts quality of life. Clinical practice guidelines (CPGs) have been developed to guide CINV management, though many patients do not receive guideline-concordant care. Few studies have examined provider perspectives on CINV management or preferred improvement approaches, or pediatric
-
Oxygen saturation thresholds in managing sickle cell disease at US children's hospitals Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-27 Aravind Yadav, Faryal Munir, Kok Hoe Chan, Mariam Z. Quraishi, Tomika S. Harris, Deborah L. Brown, Neethu Menon, Trinh T. Nguyen, Lakshmi Srivaths
Adequate oxygen saturation (SpO2) is crucial for managing sickle cell disease (SCD). Children with SCD are at increased risk for occult hypoxemia; therefore, understanding SpO2 threshold practices would help identify barriers to oxygen optimization in a population sensitive to oxyhemoglobin imbalances. We investigated SpO2 cutoff levels used in clinical algorithms for management of acute SCD events
-
Implementation of a tier system for IVIG indications to address IVIG shortage at a tertiary care pediatric medical center Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-27 Kristina Roth, Christina Darwish, Michael D. Keller, Benjamin Hammer, Sameeva Ahmed-Winston, Enrique Escalante, Vanessa Madrigal, DiAnthia Patrick, Yaser Diab, Christina Grant, Benjamin Hanisch, Ilana Kahn, Sairah Khan, Asha Moudgil, Birte Wistinghausen
Drug shortages are a common issue that healthcare systems face and can result in adverse health outcomes for patients requiring inferior alternate treatment. The United States recently experienced a national drug shortage of intravenous immunoglobulin (IVIG). Several reported strategies to address the IVIG and other drug shortages have been proposed; however, there is a lack of evidence-based methods
-
“Just let me go”; When suicidal ideation and goals of care collide in adolescent cancer at the end of life Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-24 Bryony Lucas, Brian Friend, Jill Ann Jarrell, Rachel Kentor
Cancer in adolescents and young adults is associated with an increased risk for suicidal ideation (SI). There are no reported pediatric oncology cases describing management of SI during end of life. We present the case of a 14-year-old male with relapsed, high-risk, B-cell acute lymphoblastic leukemia who received a haploidentical stem cell transplant and was suicidal at various points in his treatment
-
Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-23 Shreya Bhasin, Joshua Brown, Anna Dorste, Chase Samsel, Lynda M. Vrooman, Anna C. Muriel
Corticosteroids are essential to curative acute lymphoblastic leukemia (ALL) treatment, yet have significant neuropsychiatric side effects that decrease quality of life for patients and families. We conducted a scoping review, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, to describe the existing measurement tools used to evaluate neurobehavioral
-
Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single-center review Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-24 Srivarshini Kanukollu, Krisoula Spatz, Jessica A. Lavery, Julia Glade Bender, Audrey Mauguen, Sherry Mathew
NK-1 receptor antagonists (NK1-RA) are key agents for chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Current pediatric practice guidelines recommend the use of intravenous fosaprepitant or oral aprepitant. However, there are reports of hypersensitivity reactions with fosaprepitant due to polysorbate 80. Intravenous aprepitant does not
-
Incidence and survival for childhood cancer by endorsed non-stage prognostic indicators in Australia Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-24 Danny R. Youlden, Sumit Gupta, A. Lindsay Frazier, Andrew S. Moore, Nicholas G. Gottardo, Joanne F. Aitken
An international expert panel recently recommended 15 ‘non-stage prognostic indicators’ (NSPIs) across eight childhood cancers, classified as essential or additional, for collection in population-based cancer registries. We aimed to describe the incidence distribution and survival of each of these NSPIs.
-
Face validity of the Kids’ ITP Tools (KIT) in the era of thrombopoietin receptor agonists Pediatr. Blood Cancer (IF 3.2) Pub Date : 2024-01-24 Catherine McGuire, Nancy L. Young, Joel Livingston, Vinita Dhir, Victor S. Blanchette, Melanie Kirby-Allen, Robert J. Klaassen
The Kids’ ITP Tools (KIT) is a questionnaire to assess quality of life of children with immune thrombocytopenia (ITP). The aim of this study was to update this previously validated tool to align with changes in clinical practice, specifically, treatment with thrombopoietin receptor agonists (TPO-RAs). Children aged 1–18 with ITP and/or their families were recruited to participate in interviews to review